KIR2DL2 Overview
Molecule Name
Killer cell immunoglobulin-like receptor 2DL2
Synonyms
CD158b1
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Background
Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.
KIR2DL2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Lirilumab | IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 | Phase 2 Clinical | Novo Nordisk A/S | Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |